Interferon beta: Phase IIa discontinued

Synairgen said AstraZeneca discontinued the double-blind, placebo-controlled, international Phase IIa INEXAS trial of inhaled AZD9412 after an interim analysis showed that an “overall very low number of reported severe exacerbations could make primary endpoint conclusions difficult.” The company said colds did not cause as many asthma exacerbations as predicted in INEXAS. The trial enrolled patients who require treatment with mid- to high-dose inhaled corticosteroids and a second controller medication and who have a history of severe exacerbations caused by cold viruses...